Targeting phosphatidylserine in anti-cancer therapy.
Targeted delivery of cytotoxic agents limits the severe toxic side-effects of anti-cancer drugs on healthy tissues. Annexin A5 is a well explored probe to target phosphatidylserine (PS)-expressing cells in vivo. Our novel understanding of the cellular and molecular mechanism of annexin A5 as a cell-entry agent and the finding that PS is expressed on living tumour as well as endothelial cells in the tumour vasculature, will allow the development of lead compounds for anti-cancer therapy.
Kenis
Heidi
H
Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, PO Box 616, 6200 MD Maastricht, the Netherlands. H.Kenis@BIOCH.unimaas.nl
Reutelingsperger
Chris
C
D000818:Animals; D017304:Annexin A5 / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects / Q000276:immunology; D015415:Biomarkers; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D008954:Models, Biological; D009369:Neoplasms / Q000188:drug therapy*; D010718:Phosphatidylserines / Q000037:antagonists & inhibitors* / Q000378:metabolism / Q000502:physiology / Q000627:therapeutic use*
D017304:Annexin A5; D000970:Antineoplastic Agents; D015415:Biomarkers; D010718:Phosphatidylserines